Equifax is in a pronounced, sustained downtrend, with the shares down 29.03% over the trailing year and 24.66% year-to-date, a stark underperformance versus the S&P 500's +15.53% one-year and +11.93% YTD returns. At $161.25, the stock sits at roughly 23.8% of its 52-week range of $137.01 to $238.94—squarely in the lower quartile—signaling persistent distribution rather than a healthy pullback, though the proximity to the 52-week low also raises the question of whether capitulation is nearing. The relative strength figures reinforce the damage: -44.56% versus SPY over one year and -36.59% YTD, among the weakest readings in large-cap industrials.\n\nShort-term momentum remains negative but is showing tentative stabilization. The one-month change of -1.56% and three-month change of -8.94% indicate the decline has decelerated from the sharper six-month drop of -17.82%, and the last two sessions printed a sharp bounce from $150.36 to $161.26 (+7.3% in a single day on October 15), suggesting buyers are defending the $140-$150 zone. That said, the one-month relative strength of -2.78% versus SPY's +1.22% confirms the stock is still lagging a rising market, a classic sign of unresolved selling pressure rather than a confirmed reversal. The bounce lacks volume confirmation in the provided data, so it should be treated as a potential oversold rally until price reclaims the $170-$175 area.\n\nKey technical levels are well defined: support sits at the 52-week low of $137.01, with a secondary shelf near $140-$145 where the September selloff found buyers; resistance is anchored at the 52-week high of $238.94, with intermediate supply likely around $175-$180 (the July-August congestion zone) and the 200-day trend area above that. A decisive break below $137 would signal a fresh leg lower and likely trigger momentum-driven selling, while a reclaim of $175 would be the first evidence of a trend change. With a beta of 1.341, Equifax is roughly 34% more volatile than the market, and its max drawdown of -47.68% underscores that position sizing and stop discipline matter materially here—the stock can move 1.3x the market in either direction.

Revenue is growing at a healthy clip and, importantly, accelerating: Q2 2026 revenue of $1.700 billion rose 10.61% year-over-year, building on Q1 2026's $1.649 billion and Q4 2025's $1.551 billion, with the sequential cadence ($1.442B in Q1 2025 to $1.700B in Q2 2026) showing consistent mid-to-high single-digit to low-double-digit expansion. Segment data shows Workforce Solutions at $705.4 million and U.S. Consumer Information Solutions at $611.6 million as the twin engines, with International contributing $383.1 million—a mix that insulates the company somewhat from pure mortgage-cycle exposure. The growth trend supports the bull case that Equifax's data assets are compounding, but the market's skepticism is that this top-line strength has not translated into proportionate earnings power.\n\nProfitability is solid but under pressure at the margin. Q2 2026 net income was $183.9 million on a 10.82% net margin, with gross margin of 54.49% and operating margin of 18.03%—respectable for a data-services franchise but below the 56.76% gross margin and 20.30% operating margin posted in Q4 2024, indicating modest compression. EBITDA of $505.6 million (29.74% EBITDA margin) remains robust, and EPS of $1.55 in Q2 2026 compares favorably to $1.54 in Q2 2025, but the flat-to-down earnings trajectory against double-digit revenue growth points to rising depreciation, interest expense ($59.8 million in Q2 2026 versus $53.1 million a year earlier), and integration costs weighing on conversion. The key question is whether operating leverage reasserts itself as the technology build matures.\n\nThe balance sheet is the pressure point: debt-to-equity of 1.106x, a current ratio of just 0.605, and cash of only $170.1 million against $59.8 million of quarterly interest expense leave limited liquidity cushion, though interest coverage of roughly 5.25x remains adequate. Free cash flow is the saving grace—TTM FCF of $1.105 billion and Q2 2026 FCF of $204.8 million against $339.8 million of operating cash flow—but capital expenditures are heavy ($135.0 million in Q2 2026) and the company is simultaneously returning capital aggressively ($300 million of buybacks and $66.4 million of dividends in Q2 alone), which is why net cash change was -$13.3 million. ROE of 14.34% and ROA of 6.16% are decent but not exceptional, and the low current ratio means Equifax depends on steady cash generation to fund both growth capex and shareholder returns—a manageable but not comfortable position.